Thrombin generation as a predictor of radiotherapy induced skin erythema

Radiotherapy and Oncology

Volumn 90, Issue 1, 2009, Pages 136-140

  Lincz, Lisa F ^a,b,c   Gupta, Sanjiv A ^a   Wratten, Christopher R ^a   Kilmurray, Janice ^a   Nash, Sharon ^a   Seldon, Michael ^a,d   O'Brien, Peter C ^a   Bell, Katy J L ^e   Denham, James W ^a  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^d HUNTER NEW ENGLAND HEALTH   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast cancer; D dimer; Plasminogen activator inhibitor 1; Prothrombin factor 1+2; Radiotherapy; Reflectance

Indexed keywords

BIOLOGICAL MARKER; D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN 1+2; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; BREAST CANCER; BREAST SURGERY; ERYTHEMA; FEMALE; HUMAN; IRRADIATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RADIATION INDUCED SKIN ERYTHEMA; REFLECTOMETRY; THROMBIN TIME;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; REGRESSION ANALYSIS; RISK FACTORS; SKIN; STATISTICS, NONPARAMETRIC;

EID: 58149234197     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.002     Document Type: Article

References (42)

1. Porock D., and Kristjanson L. Skin reactions during radiotherapy for breast cancer: the use and impact of topical agents and dressings. Eur J Cancer Care (Engl) 8 (1999) 143-153
2. Archambeau J.O., Pezner R., and Wasserman T. Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 31 (1995) 1171-1185
3. Tucker S.L., Turesson I., and Thames H.D. Evidence for individual differences in the radiosensitivity of human skin. Eur J Cancer 28A (1992) 1783-1791
4. Sitton E. Early and late radiation-induced skin alterations. Part I: Mechanisms of skin changes. Oncol Nurs Forum 19 (1992) 801-807
5. Hamilton C.S., Denham J.W., O'Brien M., Ostwald P., Kron T., Wright S., et al. Underprediction of human skin erythema at low doses per fraction by the linear quadratic model. Radiother Oncol 40 (1996) 23-30
6. Twardella D., Popanda O., Helmbold I., Ebbeler R., Benner A., von Fournier D., et al. Personal characteristics, therapy modalities and individual DNA repair capacity as predictive factors of acute skin toxicity in an unselected cohort of breast cancer patients receiving radiotherapy. Radiother Oncol 69 (2003) 145-153
7. Wells M., Macmillan M., Raab G., MacBride S., Bell N., MacKinnon K., et al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol 73 (2004) 153-162
8. Porock D., Kristjanson L., Nikoletti S., Cameron F., and Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum 25 (1998) 1019-1029
9. Denham J.W., Hamilton C.S., Simpson S.A., Ostwald P.M., O'Brien M., Kron T., et al. Factors influencing the degree of erythematous skin reactions in humans. Radiother Oncol 36 (1995) 107-120
10. Simonen P., O'Brien M., Hamilton C., Ashcroft J., and Denham J. Normal variation in cutaneous blood content and red blood cell velocity in humans. Physiol Meas 18 (1997) 155-170
11. Fiets W.E., van Helvoirt R.P., Nortier J.W., van der Tweel I., and Struikmans H. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. a prospective, comparative, non-randomised study. Eur J Cancer 39 (2003) 1081-1088
12. Fernet M., and Hall J. Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst) 3 (2004) 1237-1243
13. Porock D. Factors influencing the severity of radiation skin and oral mucosal reactions: development of a conceptual framework. Eur J Cancer Care (Engl) 11 (2002) 33-43
14. Asero R., Tedeschi A., Riboldi P., and Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 117 (2006) 1113-1117
15. Asero R., Tedeschi A., Riboldi P., Griffini S., Bonanni E., and Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 63 (2008) 176-180
16. Asero R., Tedeschi A., Coppola R., Griffini S., Paparella P., Riboldi P., et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 119 (2007) 705-710
17. Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
18. Zwicker J.I., Furie B.C., and Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 62 (2007) 126-136
19. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110 (2007) 1723-1729
20. Caine G.J., Stonelake P.S., Lip G.Y., and Kehoe S.T. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4 (2002) 465-473
21. Edwards R.L., Rickles F.R., Moritz T.E., Henderson W.G., Zacharski L.R., Forman W.B., et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88 (1987) 596-602
22. Ozyilkan O., Baltali E., Ozdemir O., Tekuzman G., Kirazli S., and Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori 84 (1998) 364-367
23. Carroll V.A., and Binder B.R. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 25 (1999) 183-197
24. Falanga A., Ofosu F.A., Delaini F., Oldani E., Dewar L., Lui L., et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 5 (1994) S19-S23 [discussion 59-64]
25. Wratten C., Kilmurray J., Nash S., Seldon M., Hamilton C.S., O'Brien P.C., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59 (2004) 160-167
26. Feather J.W., Hajizadeh-Saffar M., Leslie G., and Dawson J.B. A portable scanning reflectance spectrophotometer using visible wavelengths for the rapid measurement of skin pigments. Phys Med Biol 34 (1989) 807-820
27. Bostrom A., Lindman H., Swartling C., Berne B., and Bergh J. Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study. Radiother Oncol 59 (2001) 257-265
28. Simonen P., Hamilton C., Ferguson S., Ostwald P., O'Brien M., O'Brien P., et al. Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans?. Radiother Oncol 46 (1998) 73-82
29. Schaeffer Jr. R.C., Gong F., Bitrick Jr. M.S., and Smith T.L. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 264 (1993) H1798-H1809
30. Sheldon P.J., Oglevie S.B., and Kaplan L.A. Prolonged generalized urticarial reaction after percutaneous thrombin injection for treatment of a femoral artery pseudoaneurysm. J Vasc Interv Radiol 11 (2000) 759-761
31. Bruhn H.D., Liebsch J., and Wagner C. Documentation of hypocoagulability by measurement of prothrombin fragment F 1+2 when introducing oral anticoagulant therapy. Thromb Res 68 (1992) 317-319
32. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3 (2005) 35-45
33. Han B., Nakamura M., Mori I., Nakamura Y., and Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep 14 (2005) 105-112
34. Harbeck N., Kates R.E., Schmitt M., Gauger K., Kiechle M., Janicke F., et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5 (2004) 348-352
35. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
36. Romer J., Bugge T.H., Pyke C., Lund L.R., Flick M.J., Degen J.L., et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 2 (1996) 287-292
37. Lund L.R., Green K.A., Stoop A.A., Ploug M., Almholt K., Lilla J., et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 25 (2006) 2686-2697
38. Lyons-Giordano B., and Lazarus G.S. Skin abnormalities in mice transgenic for plasminogen activator inhibitor 1: implications for the regulation of desquamation and follicular neogenesis by plasminogen activator enzymes. Dev Biol 170 (1995) 289-298
39. Chan J.C., Duszczyszyn D.A., Castellino F.J., and Ploplis V.A. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159 (2001) 1681-1688
40. Burzotta F., Di Castelnuovo A., Amore C., D'Orazio A., Di Bitondo R., Donati M.B., et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 79 (1998) 354-358
41. Eriksson P., Kallin B., Van't Hooft F.M., Bavenholm P., and Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92 (1995) 1851-1855
42. Kasperska-Zajac A., Brzoza Z., and Rogala B. Blood urokinase plasminogen activator system in chronic urticaria. Arch Dermatol Res 298 (2007) 409-411